Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Carolina Actimmune Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    ACTIMMUNE (S) Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Actimmune injection under the South Carolina PDP Basic benefit. Coverage applies to members with chronic granulomatous disease or severe malignant osteopetrosis and includes continuation of prior therapy.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTIMMUNE (S) Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of chronic granulomatous disease or severe malignant osteopetrosis; for continuation, document ongoing Actimmune therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ActimmuneProduct affected
    2Covered diagnostic indications
    12 monthsCoverage duration
    Not requiredPrerequisite Part D drug

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Actimmune Coverage Criteria

    Initial Therapy — Eligible Indications

    Actimmune is covered for initial therapy when ALL of the following criteria are met:

    ALL of the following

    • The member has chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO).
    • The requested use is medically accepted for the diagnosed condition.
    • The diagnosis is documented in the medical record.

    Continuation Therapy

    Continuation therapy may be approved when ALL of the following criteria are met:

    ALL of the following

    • The member is continuing prior Actimmune therapy.
    • The member continues to have chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO).
    • The prescriber documents that continued therapy remains medically necessary.

    Initial Actimmune Therapy — Medically Accepted Indications and Diagnosis Documentation

    Actimmune is covered for all medically accepted indications when the required diagnosis documentation is provided.

    ALL of the following

    • The requested indication is medically accepted.
    • ONE of the following diagnoses is documented

      • Chronic granulomatous disease (CGD).
      • Severe malignant osteopetrosis (SMO).

    Continuation of Actimmune — Prior Therapy

    Continuation of prior Actimmune therapy may be approved for a member who continues to meet coverage requirements.

    ALL of the following

    • The member has received prior Actimmune therapy.
    • The member continues to have a covered diagnosis of chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO).
    • Continued treatment is supported by current clinical documentation.

    Prior Authorization and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Actimmune INJ 100MCG/0.5ML before coverage can be approved.

    • Product: Actimmune INJ 100MCG/0.5ML
    • Coverage duration: 12 months
    Documentation Required

    Required Medical Information

    Submit documentation confirming the diagnosis and, for continuation requests, documentation supporting ongoing therapy.

    • Diagnosis of chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO)
    • Continuation of prior therapy, when applicable
    Denial Risk

    Eligible Diagnosis Required

    Coverage requires documentation establishing one of the eligible diagnoses. Requests that do not establish chronic granulomatous disease or severe malignant osteopetrosis may be denied.

    • Chronic granulomatous disease (CGD)
    • Severe malignant osteopetrosis (SMO)

    Policy Background

    Actimmune injection 100 mcg/0.5 mL is subject to prior authorization for medically accepted use in patients diagnosed with chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO). The policy authorizes coverage for 12 months and allows continuation of prior Actimmune therapy. No additional age, prescriber, or prerequisite Part D drug requirement is specified.

    Relevant Terms

    Definition
    AbbreviationCGD
    Full termChronic granulomatous disease
    Policy relevanceAn eligible diagnosis for Actimmune coverage
    Definition
    AbbreviationSMO
    Full termSevere malignant osteopetrosis
    Policy relevanceAn eligible diagnosis for Actimmune coverage
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTIMMUNE (S) Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of chronic granulomatous disease or severe malignant osteopetrosis; for continuation, document ongoing Actimmune therapy.
    SourceLink
    On This Page
    Actimmune Coverage CriteriaPrior Authorization and Submission RequirementsPolicy BackgroundRelevant Terms